Visionary Holdings and Jiangsu Yike Regenerative Medical Technology Establish Joint Venture to Commercialize Stem Cell Therapy for Diabetes Remission in $150 Billion Market
ByAinvest
Wednesday, Oct 22, 2025 9:33 am ET1min read
NAMI--
Jinxin Technology Holding Company announced a $2 million share repurchase program, allowing the company to repurchase its ordinary shares until October 21, 2026. The repurchases may be made through open market purchases, privately negotiated transactions, or block trades, depending on market conditions. The company's board of directors will review the program periodically and may adjust its terms, suspend or discontinue it at any time. The repurchases will be funded by the company's existing cash balance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet